ArticleJournal of clinical pathology1992
Prognostic value of c-erbB-2 expression in uterine cervical carcinoma.
Article in Journal of clinical pathology, 1992. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 1 synthesis or guideline pooled it, 66 citations in OpenAlex.
- Prevalence of HER2 overexpression and amplification in cervical cancer: A systematic review and meta-analysis.PloS one · 2021Pooled it
- Trastuzumab deruxtecan (T-DXd) in HER2-expressing gynecological malignancies: Clinical evidence, safety profile, and future directions.Gynecologic oncology reports · 2026Review
- EGFR, HER2, and MET gene amplification and protein expression profiles in biliary tract cancer and their prognostic significance.The oncologist · 2024Article
- EGFR and HER2 expression in cervical cancer patients in Ibadan, Nigeria.Ecancermedicalscience · 2023Article
- Genomic abnormalities in invasive endocervical adenocarcinoma correlate with pattern of invasion: biologic and clinical implications.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2017Article
- Prognostic significance of the co-expression of EGFR and HER2 in adenocarcinoma of the uterine cervix.PloS one · 2017Article
- HER2 expression beyond breast cancer: therapeutic implications for gynecologic malignancies.Molecular diagnosis & therapy · 2013Review
- Systemic therapy for advanced or recurrent endometrial carcinoma.Current oncology reports · 1999Review
- C-erbB-2 immunostaining: problems with interpretation.Journal of clinical pathology · 1994Article
- Prostatic carcinoma: a multivariate analysis of prognostic factors.British journal of cancer · 1994Article
- Hormone resistant prostatic adenocarcinoma. An evaluation of prognostic factors in pre- and post-treatment specimens.British journal of cancer · 1993Article
- Prognostic value of epidermal growth factor receptor expression in cervical carcinoma.Journal of clinical pathology · 1993Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsTo study the pattern of expression and prognostic importance of c-erbB-2 protein in cervical carcinoma.
methodsSixty two cases of stage IB/IIA cervical carcinoma, representing the three main tumour types, were investigated immunohistochemically for the presence of c-erbB-2 protein expression, using a monoclonal antibody (CB11) to its internal domain. Follow up of at least five years' duration was available in all cases.
resultsDefinite membrane staining was seen in 38.7% of cases. There was a strong correlation with poor survival (p less than 0.0001) particularly. For those with adenocarcinomas, this was the case when nodal metastases were present. In contrast, for squamous carcinomas and adenosquamous carcinomas, the association with a poor prognosis was most apparent in those patients without lymph node metastases.
conclusionsThese findings raise the possibility that immunostaining for c-erbB-2 protein could be used as a prognostic marker and may help identify those patients for whom early adjuvant treatment might be beneficial.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.